Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Pacira BioSciences (PCRX)

Pacira reports 2025 revenue of $726.4 million; Q4 net income falls to $1.6 million

Mixed Impact 3 of 5 earnings Written later

Pacira reported fourth-quarter 2025 revenue of $196.9 million, up 5 percent, and GAAP net income of $1.6 million, or $0.04 per diluted share, down from $16.0 million, or $0.34 per diluted share, a year earlier. For full-year 2025, revenue rose 4 percent to $726.4 million and GAAP net income was $7.0 million, compared with a net loss of $99.6 million in 2024. The company also issued 2026 guidance for total revenue of $745 million to $770 million.

Key points

  • Q4 2025 total revenue was $196.9 million, up 5 percent from $187.3 million; EXPAREL net product sales were $155.8 million, up 5 percent.
  • Q4 2025 total operating expenses were $194.5 million versus $162.5 million; SG&A was $101.6 million versus $79.6 million, which the company said included unanticipated business development due diligence and litigation costs.
  • Q4 2025 non-GAAP net income was $24.4 million, or $0.57 per diluted share, compared with $44.3 million, or $0.91 per diluted share, in Q4 2024.
  • 2026 guidance: EXPAREL net product sales of $600 million to $620 million and total revenue of $745 million to $770 million.

The filing

CompanyPacira BioSciences (PCRX)
Form8-K, current report
Filed with the SECFeb 26, 2026, 4:02 PM ET
Accession number0001628280-26-012238

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:57 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 26, 2026.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.